Login
$TIL
$5.75 -$0.33 (5.43%) Live

$TIL SEC Filings

Filed On Filing
16 Nov 2026 10-Q
16 Nov 2026 8-K: Results of Operations and Financial Condition

(Former Name or Former Address, if Changed Since Last Report)

13 Aug 2026 10-Q
13 Aug 2026 8-K: Results of Operations and Financial Condition

DALLAS, TX, August 13, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its second quarter 2026 financial results and...

12 Jun 2026 Form 4: McGaughy R Kent Jr, Director

Granted 6,500 Stock Option (Right to Buy)

12 Jun 2026 Form 4: Matcham George, Director

Granted 6,500 Stock Option (Right to Buy)

12 Jun 2026 Form 4: Gibson Neil W, Director

Granted 0 Stock Option (Right to Buy)

12 Jun 2026 Form 4: Binder Gwendolyn, Director

Granted 6,500 Stock Option (Right to Buy)

11 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 11, 2026, Instil Bio, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on two proposals, each of which is described in more detail i...

15 May 2026 10-Q
15 May 2026 8-K: Results of Operations and Financial Condition

DALLAS, TX, May 15, 2026 (GLOBE NEWSWIRE) - Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its first quarter 2026 financial results and prov...

24 Apr 2026 ARS
24 Apr 2026 DEFA14A
24 Apr 2026 Proxy statement: annual meeting on June 11, 2026
03 Apr 2026 8-K: Changes in Registrant's Certifying Accountant

We have read Item 4.01 of Instil Bio, Inc.'s Form 8-K dated April 3, 2026, and have the following comments:

27 Mar 2026 S-8
27 Mar 2026 10-K
27 Mar 2026 8-K: Results of Operations and Financial Condition

Company evaluating potential acquisitions and in-licensing opportunities to drive next phase of strategic development

09 Feb 2026 SCHEDULE 13G/A
06 Jan 2026 8-K: Termination of a Material Definitive Agreement

On January 5, 2026, Axion Bio, Inc. (“Axion”), a wholly-owned subsidiary of Instil Bio, Inc., and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (“ImmuneOnco”) entered into an agreement terminating, effective January 5, 2026, the License ...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support